Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients

Figure 2 Relationship of hepatitis B virus RNA to other biomarkers. A: In the virological response (VR) group, there was a moderate correlation between hepatitis B virus (HBV) RNA and HBV DNA before treatment; B: In the partial (VR) PVR group, there was no correlation between HBV RNA and HBV DNA before treatment; C: After 24 wk of treatment, HBV RNA and HBV DNA had a moderate correlation in the PVR group; D: In the VR group, HBV RNA and HBsAg had no correlation before treatment; E: In the PVR group, HBV RNA and HBsAg had no correlation before treatment; F: After 24 wk of treatment, HBV RNA had no correlation with HBsAg in the VR group; G: After 24 wk of treatment, HBV RNA had a significant high correlation with HBsAg in the PVR group; H: HBV RNA had no correlation with HBsAg in group A before treatment; I: HBV RNA had no correlation with HBsAg in group A after treatment; J: HBV RNA had no correlation with HBV DNA in group A before treatment; K: HBV RNA had a moderate correlation with HBV DNA in group A after treatment; L: HBV RNA had no correlation with HBsAg in group B before treatment; M: HBV RNA had no correlation with HBsAg in group B after treatment; N: HBV RNA had no correlation with HBV DNA in group B before treatment; O: HBV RNA had a moderate correlation with HBV DNA in group B after treatment. HBV: Hepatitis B virus; VR: Virological response; PVR: Partial virological response.